Immunitybio, Inc. (IBRX) — 10-Q Filings
All 10-Q filings from Immunitybio, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
- 10-Q Filing — May 7, 2026
-
ImmunityBio's Q2 Losses Widen Amidst Revenue Dip
— Aug 5, 2025 Risk: high
ImmunityBio, Inc. reported a net loss of $105.8 million for the three months ended June 30, 2025, a significant increase from the $90.2 million net loss in the -
ImmunityBio Files Q1 2025 10-Q
— May 12, 2025 Risk: medium
ImmunityBio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as NantKwest, Inc., is involved in the biological products se -
ImmunityBio Files Q3 2024 10-Q
— Nov 12, 2024 Risk: medium
ImmunityBio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its business opera -
ImmunityBio Files Q2 2024 10-Q
— Aug 12, 2024 Risk: medium
ImmunityBio, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly NantKwest, Inc., is involved in biological products. Key financial d -
ImmunityBio, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: low
ImmunityBio, Inc. (IBRX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. ImmunityBio, Inc. filed a 10-Q report for the period ending March 31, 2024
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX